BTF3通过转录上调PDCD2L和失活p53信号传递来影响肝细胞癌的进展
Minyu Kong1,2,3,4, Xiaoyi Shi1,2,3,4, Jie Gao1,2,3,4
1Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Molecular medicine (Cambridge, Mass.)
|December 20, 2024
概括
通过增加PDCD2L转录,BTF3促进肝细胞癌 (HCC) 的进展,影响p53通路. 针对BTF3/PDCD2L/p53轴为HCC提供了一个潜在的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 肝细胞癌 (HCC) 是一种普遍存在的恶性瘤,存活率较低.
- 对于BTF3和PDCD2L在HCC病变发生中的特定作用尚不完全了解.
- 识别新的分子标对于改善HCC治疗结果至关重要.
研究的目的:
- 研究BTF3和PDCD2L在肝细胞癌中的功能作用.
- 阐明BTF3影响HCC进展的潜在分子机制.
- 评估BTF3/PDCD2L/p53信号轴作为HCC的治疗点的潜力.
主要方法:
- 在HCC组织中分析BTF3表达和与患者预后的相关性.
- 在HCC细胞中BTF3敲击后的细胞功能测定 (增殖和亡).
- 研究BTF3对PDCD2L转录的调节作用及其对p53通路的影响.
主要成果:
- 在HCC组织中,BTF3表达显著上调,与预后不佳有关.
- 抑制BTF3可以抑制HCC细胞的增殖,并诱导细胞亡.
- BTF3充当瘤转录因子,调节PDCD2L表达并抑制p53通路,从而促进HCC细胞的增殖和抑制细胞亡.
结论:
- BTF3通过转录激活PDCD2L来驱动HCC的恶性进展,这反过来抑制了p53通路.
- 已确定的BTF3/PDCD2L/p53轴代表了肝细胞癌患者有前途的治疗策略.
关键词:
BTF3BTF3BTF3BTF3BTF3BTF3BTF3BTF3BTF3BTF3BTF3BTF3BTF3BTF3BTF3BTF3BTF3BTF3B肝细胞癌是肝细胞癌.在PDCD2L中使用.在 p53 里,p53 是一个 p53 的类型.更多相关视频
00:06An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
8.8K
09:11Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
381
相关概念视频
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Interactions Between Signaling Pathways
6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
